Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Hayley Ma, Bao Nguyen, Li Li, Sarah Greenblatt, Allen Williams, Ming Zhao, Mark Levis, Michelle Rudek, Amy Duffield, Donald Small

Blood (2014) 123 (10): 1525–1534.

https://doi.org/10.1182/blood-2013-08-523035

Published: 2014

Includes: Supplemental data

Journal Articles

Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors

Allen Williams, PhD, Li Li, PhD, Bao Nguyen, M.S., Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2011) 118 (21): 1421.

https://doi.org/10.1182/blood.V118.21.1421.1421

Published: 2011

Journal Articles

Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells

Allen Williams, PhD, Bao Nguyen, M.S., Li Li, PhD, Patrick Brown, MD, Mark J. Levis, MD, PhD, Donald Small, MD, PhD

Blood (2010) 116 (21): 779.

https://doi.org/10.1182/blood.V116.21.779.779

Published: 2010

Journal Articles

Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.

Allen Williams, PhD, Bao Nguyen, Mark Levis, Patrick Brown, MD, Donald Small, MD, PhD

Blood (2009) 114 (22): 3776.

https://doi.org/10.1182/blood.V114.22.3776.3776

Published: 2009

Journal Articles

Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD.

Allen Williams, PhD, Sina Koch, PhD, Thiede Christian, Ph.D., Patrick Brown, MD, Mark Levis, Donald Small, MD, PhD

Blood (2009) 114 (22): 2748.

https://doi.org/10.1182/blood.V114.22.2748.2748

Published: 2009

Journal Articles

Possible Role of the Activation Loop Tyrosine Residue (Y842) in FLT3/ITD Signaling May Be Mediated by SHP-2.

Peili Chen, PhD, Allen Williams, PhD, Henrik Molina, Akhilesh Pandey, MD, PhD, Donald Small, MD, PhD

Blood (2005) 106 (11): 1199.

https://doi.org/10.1182/blood.V106.11.1199.1199

Published: 2005

NARROW

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors

Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells

Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.

Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD.

Possible Role of the Activation Loop Tyrosine Residue (Y842) in FLT3/ITD Signaling May Be Mediated by SHP-2.

Email alerts

ASH Publications

American Society of Hematology

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo

Statin Treatment Prevents FLT3 Glycosylation and Overcomes Resistance to FLT3 Tyrosine Kinase Inhibitors

Statin Treatment Inhibits FLT3 Signaling by Preventing Glycosylation of the Mature Receptor and Leads to Cell Death In Mutant FLT3 Expressing Cells

Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.

Glycosylation and Surface Localization Are Required for FLT3 Activation but Not for FLT3/ITD.

Possible Role of the Activation Loop Tyrosine Residue (Y842) in FLT3/ITD Signaling May Be Mediated by SHP-2.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only